View More
Learn how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.
Latesha Elopre, MD, MSPH
Released: June 7, 2021
Download this PDF to share with your patients who are interested in HIV pre-exposure prophylaxis
Jason Schafer, PharmD, MPH
Released: February 24, 2022
Listen as Latesha Elopre, MD, MSPH, explains how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.
Latesha Elopre, MD, MSPH
Released: July 7, 2021
See how to initiate PrEP in underserved communities, with examples on overcoming barriers and improving access.
Latesha Elopre, MD, MSPH
Released: June 7, 2021
In this case example, learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
Jason Schafer, PharmD, MPH
Released: February 8, 2022
Learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
Jason Schafer, PharmD, MPH
Released: February 16, 2022
Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
Jason Schafer, PharmD, MPH
Released: March 14, 2022
As a gay man who is also a physician, I am considering long-acting PrEP but have many questions about how it would work in my life.
Anonymous Patient
Released: February 3, 2022
Important considerations for PrEP in transgender individuals include choosing the right PrEP option and addressing stigma to improve adherence.
Karine Lacombe, MD, PhD
Released: April 15, 2022
Adherence and accessibility are critical to improving uptake and effectiveness of PrEP for PWID.
Karine Lacombe, MD, PhD
Released: April 15, 2022
In this case example, learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.
Jason Schafer, PharmD, MPH
Released: February 16, 2022
Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.
Jason Schafer, PharmD, MPH
Released: March 21, 2022
Learn some of the key considerations for using long-acting injectable cabotegravir for PrEP including management of missed dosing, stopping PrEP, and screening for HIV while on PrEP.
Jason Schafer, PharmD, MPH
Released: March 15, 2022
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: March 24, 2022
Learn key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: February 15, 2022
Learn key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: February 15, 2022
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: March 25, 2022
Australian study shows overwhelming demand and uptake of PrEP and highlights the power of partnering among government, clinical, and academic institutions.
Don Smith, MD
Released: March 18, 2022
In this case example, learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: April 26, 2022
Learn data and recommendations for HIV postexposure prophylaxis, including currently recommended regimens, single tablet regimens, and PrEP following PEP.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: April 29, 2022
Listen as Dr Michelle D. Collins-Ogle shares data and recommendations for HIV PEP, including currently recommended regimens, single-tablet regimens, and pre-exposure prophylaxis following PEP.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.